Paper Details

  1. Home
  2. Paper Details

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.

Author: , ArnoldDirk, BassamAli, ChongGeoff, CremoliniChiara, CsősziTibor, Cubillo GracianAntonio, DasariArvind, DucreuxMichel, ElezElena, ElmeAnneli, EngCathy, FaugerasLaurence, Garcia-CarboneroRocio, García-AlfonsoPilar, GhiringhelliFrancois, HochsterHoward S, JonesJeremy, KaniaMarek, KasperStefan, KocsisJudit, KraussJohn, LonardiSara, MasuishiToshiki, NandaShivani, PaulsonAndrew Scott, RandrianViolaine, Sartore-BianchiAndrea, SatohTaroh, SchelmanWilliam R, ShergillArdaman, SobreroAlberto, TaberneroJosep, TomasekJiri, Van CutsemEric, YangZhao, YaoJames, YoshinoTakayuki

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study examines the efficacy and safety of fruquintinib, an oral inhibitor of vascular endothelial growth factor receptors (VEGFRs), in patients with heavily pretreated metastatic colorectal cancer. The study seeks to provide new treatment options for patients with advanced and refractory colorectal cancer.
Paper Details　
Original Abstract of the Article :
There is a paucity of effective systemic therapy options for patients with advanced, chemotherapy-refractory colorectal cancer. We aimed to evaluate the efficacy and safety of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2, an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(23)00772-9

データ提供：米国国立医学図書館（NLM）

Fruquintinib: A Hope for Refractory Colorectal Cancer?

In the vast desert of cancer research, we are constantly seeking new oases of hope. This study delves into the intriguing world of colorectal cancer, a challenging foe that often becomes refractory to traditional therapies. The researchers, driven by the need for new weapons against this formidable enemy, set out to explore the potential of fruquintinib, an orally administered inhibitor of vascular endothelial growth factor receptors (VEGFRs).

Fruquintinib Shows Promise in Combating Refractory Colorectal Cancer

The results of this study, like a refreshing spring in the desert, offer a glimmer of hope for patients struggling with heavily pretreated metastatic colorectal cancer. Fruquintinib, acting as a potent inhibitor of VEGFRs, demonstrated its potential to effectively combat this disease.

A New Frontier in Colorectal Cancer Treatment

This study, like a beacon in the night, sheds light on a promising new avenue for treating refractory colorectal cancer. Fruquintinib's ability to target VEGFRs, crucial for tumor growth, suggests a potential shift in the landscape of colorectal cancer treatment.

Dr. Camel's Conclusion

Fruquintinib emerges as a potential oasis in the desert of refractory colorectal cancer. This promising new drug, targeting VEGFRs, could offer a lifeline to patients facing limited treatment options. As we continue to explore the vast desert of cancer research, fruquintinib holds great promise for a brighter future for colorectal cancer patients.

Date :
  1. Date Completed 2023-07-03
  2. Date Revised 2023-11-16
Further Info :

Pubmed ID

37331369

DOI: Digital Object Identifier

10.1016/S0140-6736(23)00772-9

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.